Scott C. Brun

2.3k total citations · 1 hit paper
16 papers, 1.8k citations indexed

About

Scott C. Brun is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Scott C. Brun has authored 16 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 13 papers in Virology and 4 papers in Emergency Medicine. Recurrent topics in Scott C. Brun's work include HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (13 papers) and HIV/AIDS Research and Interventions (10 papers). Scott C. Brun is often cited by papers focused on HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (13 papers) and HIV/AIDS Research and Interventions (10 papers). Scott C. Brun collaborates with scholars based in United States, United Kingdom and Spain. Scott C. Brun's co-authors include Martin King, Dale J. Kempf, George J. Hanna, Barry Bernstein, Sarah Palmer, Frank Maldarelli, John W. Mellors, John M. Coffin, Ann Wiegand and Eugene Sun and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Virology and The Journal of Infectious Diseases.

In The Last Decade

Scott C. Brun

16 papers receiving 1.7k citations

Hit Papers

Low-level viremia persists for at least 7 years in patien... 2008 2026 2014 2020 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
    2008 514 citations Sarah Palmer, Frank Maldarelli et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott C. Brun United States 15 1.5k 1.4k 392 183 158 16 1.8k
Hans-Jürgen Stellbrink Germany 10 1.4k 0.9× 1.1k 0.8× 584 1.5× 257 1.4× 106 0.7× 12 1.7k
Nicola Gianotti Italy 21 1.2k 0.8× 1.1k 0.8× 305 0.8× 306 1.7× 58 0.4× 153 1.5k
Barbara Gripshover United States 15 809 0.5× 627 0.4× 413 1.1× 293 1.6× 135 0.9× 48 1.2k
Benoît Trottier Canada 19 1.7k 1.1× 1.5k 1.1× 374 1.0× 390 2.1× 261 1.7× 68 2.2k
Clare Brennan United States 13 1.3k 0.9× 1.0k 0.7× 346 0.9× 299 1.6× 50 0.3× 20 1.6k
Franco Maggiolo Italy 12 1.0k 0.7× 837 0.6× 341 0.9× 280 1.5× 42 0.3× 28 1.3k
Brian Wynhoven Canada 21 1.7k 1.1× 1.5k 1.1× 362 0.9× 448 2.4× 130 0.8× 30 2.1k
Erin Quirk United States 19 1.6k 1.0× 1.2k 0.8× 605 1.5× 277 1.5× 46 0.3× 42 1.8k
Joseph Quinn United States 11 1.3k 0.9× 1.0k 0.7× 171 0.4× 351 1.9× 54 0.3× 14 1.6k
George J. Hanna United States 29 2.6k 1.7× 2.4k 1.7× 434 1.1× 456 2.5× 216 1.4× 77 3.1k

Countries citing papers authored by Scott C. Brun

Since Specialization
Citations

This map shows the geographic impact of Scott C. Brun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott C. Brun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott C. Brun more than expected).

Fields of papers citing papers by Scott C. Brun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott C. Brun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott C. Brun. The network helps show where Scott C. Brun may publish in the future.

Co-authorship network of co-authors of Scott C. Brun

This figure shows the co-authorship network connecting the top 25 collaborators of Scott C. Brun. A scholar is included among the top collaborators of Scott C. Brun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott C. Brun. Scott C. Brun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Murphy, Robert L., Barbara A. da Silva, Charles B. Hicks, et al.. (2008). Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral—Naïve HIV-1-Infected Patients. HIV Clinical Trials. 9(1). 1–10. 52 indexed citations
2.
Cameron, D. William, Barbara A. da Silva, José Ramón Arribas, et al.. (2008). A 96‐Week Comparison of Lopinavir‐Ritonavir Combination Therapy Followed by Lopinavir‐Ritonavir Monotherapy versus Efavirenz Combination Therapy. The Journal of Infectious Diseases. 198(2). 234–240. 88 indexed citations
3.
Palmer, Sarah, Frank Maldarelli, Ann Wiegand, et al.. (2008). Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences. 105(10). 3879–3884. 514 indexed citations breakdown →
4.
Klein, Cheri E., Yi‐Lin Chiu, Walid M. Awni, et al.. (2007). The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect. JAIDS Journal of Acquired Immune Deficiency Syndromes. 44(4). 401–410. 117 indexed citations
5.
Maldarelli, Frank, Sarah Palmer, Martin King, et al.. (2007). ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia. PLoS Pathogens. 3(4). e46–e46. 267 indexed citations
6.
Podzamczer, Daniel, Martin King, Cheri E. Klein, et al.. (2007). High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients: Efficacy, Safety, and Predictors of Response. HIV Clinical Trials. 8(4). 193–204. 14 indexed citations
7.
Sprinz, Eduardo, Michelle P. Luo, Kathryn R. King, et al.. (2006). Substitution with Lopinavir/Ritonavir Improves Patient-Reported Outcomes Including Quality of Life in Patients Who Were Intolerant to Their Antiretroviral Therapy. HIV Clinical Trials. 7(6). 291–308. 10 indexed citations
8.
Johnson, Margaret, Joseph Gathe, Daniel Podzamczer, et al.. (2006). A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(2). 153–160. 98 indexed citations
9.
Peng, Joanna, Federico Pulido, Jianling Li, et al.. (2006). Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus–Coinfected Subjects With Hepatic Impairment. The Journal of Clinical Pharmacology. 46(3). 265–274. 34 indexed citations
10.
King, Martin, Scott C. Brun, & Dale J. Kempf. (2005). Relationship between Adherence and the Development of Resistance in Antiretroviral‐Naive, HIV‐1–Infected Patients Receiving Lopinavir/Ritonavir or Nelfinavir. The Journal of Infectious Diseases. 191(12). 2046–2052. 68 indexed citations
11.
King, Martin, Barry Bernstein, Sharon Walmsley, et al.. (2004). Baseline HIV‐1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy–Naive Patients. The Journal of Infectious Diseases. 190(2). 280–284. 28 indexed citations
12.
Hicks, Charles B., Martin King, Roy M. Gulick, et al.. (2004). Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients. AIDS. 18(5). 775–779. 85 indexed citations
13.
14.
Kempf, Dale J., Jeffrey D. Isaacson, Martin King, et al.. (2002). Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy. Antiviral Therapy. 7(3). 165–174. 93 indexed citations
15.
16.
Brun, Scott C. & Frederick A. Jakobiec. (1997). Kaposi??s Sarcoma of the Ocular Adnexa. International Ophthalmology Clinics. 37(4). 25–38. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans-Jürgen Stellbrink Breakdown of academic impact, for papers by Nicola Gianotti Breakdown of academic impact, for papers by Barbara Gripshover Breakdown of academic impact, for papers by Benoît Trottier Breakdown of academic impact, for papers by Clare Brennan Breakdown of academic impact, for papers by Franco Maggiolo Breakdown of academic impact, for papers by Brian Wynhoven Breakdown of academic impact, for papers by Erin Quirk Breakdown of academic impact, for papers by Joseph Quinn Breakdown of academic impact, for papers by George J. Hanna
Rankless by CCL
2026